Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 5/20 | 0.48 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564124 | 0.83 | KDM4E (0.75) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL28580476 | 0.82 | KDM4E (0.62) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL10014153 | 0.82 | KCNH2 (0.55) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL29393776 | 0.82 | KDM4E (0.65) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL483223 | 0.82 | KDM4E (0.65) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL541514 | 0.81 | KDM4E (0.64) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL5792882 | 0.81 | GSK3B (0.55) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL14208183 | 0.81 | KCNH2 (0.55) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL541515 | 0.81 | KDM4E (0.64) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL28424222 | 0.81 | KDM4E (0.64) | KCNH2KDM4EHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR (HR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR (HR) | 2008-12-18 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | KCNH2 4040/4885KDM4E 2612/4885HPGD 1842/4885 |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | IL4I1, IL4, TLR5 | KCNH2 3759/4885KDM4E 1535/4885HPGD 2512/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | KCNH2 2240/4885KDM4E 620/4885HPGD 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.